Inactive Instrument

Arix Bioscience plc

Equities

ARIX

GB00BD045071

Investment Management & Fund Operators

Arix Bioscience shares suspended ahead of RTW takeover

February 12, 2024 at 07:54 am EST

Arix Bioscience PLC - London-based venture capital firm focused on biotechnology companies - Shares suspended from the London Stock Exchange amid the company's acquisition by RTW Biotech Opportunities Ltd, a New York-based investment firm focused on the life sciences sector.

In November, RTW agreed to acquire the entirety of Arix's assets, with shareholders receiving 1.4633 RTW shares for each share in the company. RTW also provided a cash exit to Arix's largest shareholder, Acacia Research Corp, which has been given a total of USD57.1 million in exchange for its 26% stake in the company.

Arix stock price: 144.00 pence each on Friday

12-month change: up 24%

RTW current stock price: 112.00p, down 0.4% on Monday

12-month change: up 6.5%

By Hugh Cameron, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Stocks mentioned in the article

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
LONDON STOCK EXCHANGE PLC	8,934 GBX	+0.49%	-0.56%	59.47B
FTSE 100	8,140 PTS	+0.75%	+3.09%	-
ACACIA RESEARCH CORPORATION	4.87 USD	-0.41%	-0.20%	487M
RTW BIOTECH OPPORTUNITIES LTD	1.31 USD	-1.13%	+1.16%	504M

Latest news about Arix Bioscience plc

Merck Sharp & Dohme LLC completed the acquisition of Harpoon Therapeutics, Inc..	Mar. 10	CI
RTW Biotech Opportunities NAV increases 2.5% in January	Feb. 14	AN
RTW Biotech Opportunities Completes Arix Bioscience Acquisition	Feb. 13	MT
RTW Biotech Opportunities Ltd a fund managed by RTW Investments, LP completed the acquisition of Arix Biosciences Plc's assets from Arix Bioscience plc.	Feb. 12	CI
Katoro Gold launches fundraising, eyes board shake-up	Feb. 12	AN
Arix Bioscience's Asset Sale to RTW Biotech Takes Effect	Feb. 12	MT
Arix Bioscience shares suspended ahead of RTW takeover	Feb. 12	AN
Arix Bioscience Shares to be Suspended on London Exchange Amid Acquisition	Feb. 12	MT
Arix Bioscience Shareholders Approve Asset Sale to RTW Biotech	Jan. 29	MT
Arix Bioscience Gains UK Regulatory Approval for Sale to RTW Biotech	Jan. 23	MT
RTW Biotech completes Arix investment in takeover run-up	Jan. 22	AN
RTW Biotech Buys Minority Stake in Arix Bioscience to Support Planned Takeover	Jan. 22	MT
Arix Bioscience plc Announces Resignation of Directors	Jan. 22	CI
Arix Bioscience eyes USD19 million return from Harpoon sale	Jan. 19	AN
Arix Bioscience Flags Proceeds from Merck's Purchase of Harpoon Therapeutics	Jan. 19	MT
Rtw Biotech Opportunities Operating Ltd completed the acquisition of a 26.6% stake in Arix Bioscience plc from Acacia Research Corporation for £47.2 million.	Jan. 18	CI
Arix Bioscience's Portfolio Company Signs $680 Million Takeover Deal with Merck & Co.	Jan. 08	MT
Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. for $410 million.	Jan. 07	CI
Arix Bioscience's Portfolio Company Doses First Patient in Late-stage Trial of Choroidal Melanoma Therapy	Dec. 08	MT
RTW Biotech Opportunities Ltd a fund managed by RTW Investments, LP agreed to acquire Arix Biosciences Plc's assets from Arix Bioscience plc for £190 million.	Nov. 30	CI
FTSE 100 Closes Up 0.28% as Interest Rate Rise Fears Start to Ease	Nov. 01	DJ
RTW Biotech agrees "immediately accretive" Arix Bioscience takeover	Nov. 01	AN
RTW Biotech Opportunities, Arix Bioscience Agree on Potential Merger Terms	Nov. 01	MT
Rtw Biotech Opportunities Operating Ltd enter into an agreement to acquire 26.6% stake in Arix Bioscience plc from Acacia Research Corporation for £47.2 million.	Oct. 31	CI
Transcript : RTW Biotech Opportunities Ltd, Arix Bioscience plc - Pre Recorded M&A Call	Oct. 31

Chart Arix Bioscience plc

Duration

Period

More charts

Company Profile

Arix Bioscience plc is a United Kingdom-based global venture capital company. The Company is focused on investing in biotechnology companies to deliver superior risk-adjusted returns to shareholders. The Company is engaged in sourcing, financing, and developing healthcare and life science businesses globally. It focuses on late pre-clinical to clinical-stage ventures and covers a diversified range of therapeutic areas. The Company's core portfolio includes Artios Pharma Limited, Aura Biosciences, Inc., Disc Medicine Inc., Ensoma, Harpoon Therapeutics, Inc., Imara, Inc., and Iterum Therapeutics Limited. Its program includes AU-011, ART4215 + talazoparib, Bitopertin, HPN328, HPN217, ART0380, ART4215, and DISC-0974. It has approximately 11 clinical trials and is conducting nine pre-clinical studies. The Company's subsidiaries include Arix Bioscience Holdings Limited, Arix Bioscience, Inc, Arix Capital Management Limited, Arthurian Life Sciences GP Limited, and ALS SPV Limited.

Sector

Investment Management & Fund Operators

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Venture Capital

	1st Jan change	Capi.
UMBRA COMPANIES INC.	+31.41%	12.02B
HERCULES CAPITAL, INC.	+14.40%	3.06B
HBM HEALTHCARE INVESTMENTS AG	+2.96%	1.42B
CION INVESTMENT CORPORATION	+1.15%	616M
VERUSA HOLDING	+35.79%	577M
MOLTEN VENTURES PLC	-10.84%	579M
OCTOPUS APOLLO VCT PLC	-4.17%	492M
WOORI TECHNOLOGY INVESTMENT CO., LTD	+33.85%	488M
BRITISH SMALLER COMPANIES VCT PLC	+3.90%	304M

Venture Capital